Regeneron Pharmaceuticals (REGN)

$803.17 +19.52 (2.49%)
Market Cap 84.41B
Revenue (ttm) 14.34B
Net Income (ttm) 4.50B
EPS (ttm) N/A
PE Ratio 21.72
Forward PE 22.47
Profit Margin 31.41%
Debt to Equity Ratio 0.06
Volume 974,800
Avg Vol 882,664
Day's Range N/A - N/A
Shares Out 105.10M
Stochastic %K 95%
Beta 0.40
Analysts Strong Sell
Price Target $868.04

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
DidYouReadThis
DidYouReadThis Feb. 15 at 7:04 PM
$REGN
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 14 at 3:13 PM
$REGN $OCUL is releasing top line P3 results on Tuesday morning regarding Axpaxli for WetAMD
0 · Reply
pnvoss
pnvoss Feb. 13 at 10:09 PM
$REGN this stock has been on fire. $SPY
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 13 at 4:46 PM
$REGN this is going for a ride today! https://media.stocktwits-cdn.com/api/3/media/10525635/medium.webp
0 · Reply
Albino_Trader123
Albino_Trader123 Feb. 13 at 4:38 PM
$REGN Looking fabulous. Nice place to be outside tech $QQQ names
0 · Reply
neanderthal_investments
neanderthal_investments Feb. 13 at 4:23 PM
$REGN shame me for cashing out at $720
0 · Reply
Iwannagofast1
Iwannagofast1 Feb. 13 at 4:17 PM
$REGN Walking it up walking it up….. Only long TSM CMG and REGN . Easy $$$ 14 shorts making even better money
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 7:43 PM
$REGN: Can Eylea HD offset the decline of its predecessor in 2026? 🤔 ⚔️ Eylea faces intense competition from Roche’s Vabysmo, impacting sales. 💉 Eylea HD shows promise with a 36% sales increase in the United States in 2025, supported by new FDA approvals. 💼 Dupixent & Libtayo continue to bolster revenue despite Eylea’s challenges. Discover how these dynamics could shape REGN’s 2026 performance 👉 https://www.zacks.com/stock/news/2862073/will-eylea-sales-decline-weigh-on-regns-top-line-in-2026?cid=sm-stocktwits-2-2862073-body-33445&ADID=SYND_STOCKTWITS_TWEET_2_2862073_BODY_33445
0 · Reply
Bates333
Bates333 Feb. 12 at 7:17 PM
$REGN bought
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 6:43 PM
Will $REGN feel the Eylea squeeze in 2026? 👀 Regeneron foresees further Eylea decline next year as biosimilars loom. The counterpunch? Eylea HD, Dupixent and Libtayo aiming to steady revenues and offset the pressure. Can the newer drivers fill the gap? Full outlook breakdown 👉 https://www.zacks.com/stock/news/2862073/will-eylea-sales-decline-weigh-on-regns-top-line-in-2026?cid=sm-stocktwits-2-2862073-teaser-33444&ADID=SYND_STOCKTWITS_TWEET_2_2862073_TEASER_33444
0 · Reply
Latest News on REGN
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

Feb 13, 2026, 5:45 AM EST - 2 days ago

Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

ASML BABA BEKE BEPC GOOG GOOGL INCY

Regeneron Announces Investor Conference Presentations

Feb 11, 2026, 4:05 PM EST - 3 days ago

Regeneron Announces Investor Conference Presentations

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Feb 10, 2026, 7:00 AM EST - 5 days ago

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Feb 2, 2026, 12:13 PM EST - 13 days ago

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Feb 2, 2026, 7:00 AM EST - 13 days ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Regeneron: Expect Double-Digit Growth In 2026

Jan 31, 2026, 8:33 AM EST - 15 days ago

Regeneron: Expect Double-Digit Growth In 2026

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Jan 30, 2026, 3:10 PM EST - 16 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Jan 30, 2026, 12:42 PM EST - 16 days ago

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Jan 30, 2026, 10:56 AM EST - 16 days ago

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30, 2026, 7:37 AM EST - 16 days ago

Regeneron beats quarterly profit estimates on Dupixent strength

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Jan 30, 2026, 6:30 AM EST - 16 days ago

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 30, 2026, 4:10 AM EST - 16 days ago

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Jan 23, 2026, 3:25 PM EST - 23 days ago

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Jan 21, 2026, 12:05 PM EST - 25 days ago

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:16 PM EST - 4 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

Jan 12, 2026, 1:30 PM EST - 4 weeks ago

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

BABA COF UNH

Regeneron Just Moved From Underperform To Buy - Here's Why

Jan 7, 2026, 4:18 PM EST - 5 weeks ago

Regeneron Just Moved From Underperform To Buy - Here's Why

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Dec 23, 2025, 1:00 AM EST - 7 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

SNY

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Dec 23, 2025, 1:00 AM EST - 7 weeks ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 4:05 PM EST - 7 weeks ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Regeneron: The Turnaround Is Gaining Steam

Dec 20, 2025, 9:30 AM EST - 2 months ago

Regeneron: The Turnaround Is Gaining Steam

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

Dec 10, 2025, 1:31 PM EST - 2 months ago

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

BKNG FISV GD

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Dec 10, 2025, 12:42 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Dec 10, 2025, 12:20 PM EST - 2 months ago

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Dec 8, 2025, 2:46 PM EST - 2 months ago

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Dec 7, 2025, 4:30 PM EST - 2 months ago

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Regeneron's experimental therapy combo effective in untreated cancer patients

Dec 6, 2025, 9:33 AM EST - 2 months ago

Regeneron's experimental therapy combo effective in untreated cancer patients

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:53 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dec 1, 2025, 7:00 AM EST - 2 months ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 2 months ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Nov 25, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

Nov 21, 2025, 11:05 AM EST - 3 months ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 20, 2025, 11:52 AM EST - 3 months ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Nov 19, 2025, 4:10 PM EST - 3 months ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Nov 19, 2025, 7:00 AM EST - 3 months ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 1:07 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 11:57 AM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Nov 13, 2025, 7:00 AM EST - 3 months ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Final Trade: LMAT, REGN, BA, TJX

Nov 12, 2025, 6:20 PM EST - 3 months ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Nov 10, 2025, 2:31 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Nov 7, 2025, 8:00 AM EST - 3 months ago

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

SNY

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Oct 29, 2025, 1:00 PM EDT - 3 months ago

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Market Starting To Embrace The 'New' Regeneron

Oct 29, 2025, 12:01 PM EDT - 3 months ago

Market Starting To Embrace The 'New' Regeneron

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:31 PM EDT - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Oct 28, 2025, 9:13 AM EDT - 3 months ago

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron beats quarterly estimates on strong demand for Dupixent

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Oct 28, 2025, 6:30 AM EDT - 3 months ago

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Has Regeneron Stock Quietly Become A Value Buy?

Oct 27, 2025, 8:35 AM EDT - 3 months ago

Has Regeneron Stock Quietly Become A Value Buy?

DidYouReadThis
DidYouReadThis Feb. 15 at 7:04 PM
$REGN
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 14 at 3:13 PM
$REGN $OCUL is releasing top line P3 results on Tuesday morning regarding Axpaxli for WetAMD
0 · Reply
pnvoss
pnvoss Feb. 13 at 10:09 PM
$REGN this stock has been on fire. $SPY
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 13 at 4:46 PM
$REGN this is going for a ride today! https://media.stocktwits-cdn.com/api/3/media/10525635/medium.webp
0 · Reply
Albino_Trader123
Albino_Trader123 Feb. 13 at 4:38 PM
$REGN Looking fabulous. Nice place to be outside tech $QQQ names
0 · Reply
neanderthal_investments
neanderthal_investments Feb. 13 at 4:23 PM
$REGN shame me for cashing out at $720
0 · Reply
Iwannagofast1
Iwannagofast1 Feb. 13 at 4:17 PM
$REGN Walking it up walking it up….. Only long TSM CMG and REGN . Easy $$$ 14 shorts making even better money
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 7:43 PM
$REGN: Can Eylea HD offset the decline of its predecessor in 2026? 🤔 ⚔️ Eylea faces intense competition from Roche’s Vabysmo, impacting sales. 💉 Eylea HD shows promise with a 36% sales increase in the United States in 2025, supported by new FDA approvals. 💼 Dupixent & Libtayo continue to bolster revenue despite Eylea’s challenges. Discover how these dynamics could shape REGN’s 2026 performance 👉 https://www.zacks.com/stock/news/2862073/will-eylea-sales-decline-weigh-on-regns-top-line-in-2026?cid=sm-stocktwits-2-2862073-body-33445&ADID=SYND_STOCKTWITS_TWEET_2_2862073_BODY_33445
0 · Reply
Bates333
Bates333 Feb. 12 at 7:17 PM
$REGN bought
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 6:43 PM
Will $REGN feel the Eylea squeeze in 2026? 👀 Regeneron foresees further Eylea decline next year as biosimilars loom. The counterpunch? Eylea HD, Dupixent and Libtayo aiming to steady revenues and offset the pressure. Can the newer drivers fill the gap? Full outlook breakdown 👉 https://www.zacks.com/stock/news/2862073/will-eylea-sales-decline-weigh-on-regns-top-line-in-2026?cid=sm-stocktwits-2-2862073-teaser-33444&ADID=SYND_STOCKTWITS_TWEET_2_2862073_TEASER_33444
0 · Reply
Iwannagofast1
Iwannagofast1 Feb. 12 at 4:45 PM
$REGN one of the few longs in my portfolio selling half at 900 where is that one dumb guy @Johny34211 ???? Hmmmmm . I bet he has had to have made numerous investments in kneepads.
0 · Reply
tasha655
tasha655 Feb. 12 at 3:40 PM
$REGN $800 is slow close!
0 · Reply
Albino_Trader123
Albino_Trader123 Feb. 12 at 3:33 PM
$REGN safe name away from Tech $XLK $QQQ names.
0 · Reply
Iwannagofast1
Iwannagofast1 Feb. 11 at 8:09 PM
$REGN This is correct . $900 on the way. Don’t gets it confused you BA MM . Remember under $500 ? me too bought at $300 and 480. Selling 1/2 att $900.
0 · Reply
Albino_Trader123
Albino_Trader123 Feb. 11 at 6:47 PM
$REGN Setting up nicely. Have some longs in. Will add more on breakou
0 · Reply
corsilt
corsilt Feb. 10 at 9:48 PM
$REGN annoying how often this tanks for no reason
0 · Reply
Quantumup
Quantumup Feb. 10 at 5:39 PM
BTIG⬆️1H26 Top Pick $NKTR's PT to $151 and reiterated at Buy $CRVS $REGN - SNY $LLY KYMR $APGE Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2021276476335636938?s=20
0 · Reply
Quantumup
Quantumup Feb. 10 at 5:21 PM
William Blair⬆️ $NKTR to Outperform and provided its Take and Stock Thoughts. $CRVS $REGN - SNY $APGE $KYMR William Blair said: Rezpeg, continues to demonstrate deepening of response and durability with longer-term data—Re: durability, WB noted, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing—noted, there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg. Here's what else William Blair had to say: https://x.com/Quantumup1/status/2021272497862115591?s=20
0 · Reply
Iwannagofast1
Iwannagofast1 Feb. 10 at 2:40 PM
$REGN $900 by June
0 · Reply
gargoyl
gargoyl Feb. 9 at 7:50 PM
$BLRX new pivot lived up to 3.82 This week 🎯 $REGN $PFE $BMY Target 🎯 $18 Long the 🦋 Phil’s 🥷 the ninja
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 9 at 5:16 AM
following my system for $REGN - only buying when H% is low like shown
0 · Reply
C3PO2099
C3PO2099 Feb. 8 at 11:48 PM
$SPY $QQQ $TQQQ $CPXR $REGN Gonna buy a few puts to hedge a drop from 29500. But other than that its will be a great year. Long 3 things: tqqq leaps, cpxr, and regn.
0 · Reply